Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report highlights significant improvement in a patient with severe alopecia areata who responded well to ivarmacitinib after a suboptimal response to another JAK inhibitor, tofacitinib, suggesting ivarmacitinib as a potential alternative for tofacitinib-refractory cases.

This study found that hollow polydopamine nanoparticles enhanced the regenerative potency of the peptide RL-QN15, suggesting potential for improved therapeutic approaches in skin wound healing.

In this case report, upadacitinib was used to treat a 21-year-old female with severe alopecia areata, resulting in significant hair regrowth; however, rapid hair loss recurred soon after discontinuing the drug, illustrating its potential efficacy as well as the risk of relapse upon stopping treatment.

The researchers reported that repurposing the drug eflornithine may offer a treatment option for Bachmann-Bupp Syndrome, highlighting a potential model for other rare diseases.

This study found that targeting RARβ and RXRA with CANA, in combination with MPA, could help overcome progestin resistance by restoring BAX levels and downregulating CRABP2, suggesting a novel strategy for improving clinical efficacy in this context.

This phase I study determined that a combination of oral SU-014813 and docetaxel is a feasible treatment with a manageable safety profile and potential anti-tumor activity, particularly noted in melanoma and GIST patients.

This study suggests that scalp rolling could be a promising and affordable adjuvant treatment for alopecia areata, potentially promoting hair regrowth by enhancing the effects of topical medications and inducing collagen.

This review discusses the side effects associated with ovarian cancer treatment and highlights the need for tools to assess, prevent, and manage these effects; it reports no clinical results.

In this case report, a 55-year-old woman developed alopecia areata approximately one year into her treatment with upadacitinib for atopic dermatitis, raising questions about a potential drug-induced link that has not been reported before.

In this case report, a 13-year-old girl with Pitt-Hopkins syndrome developed hair curling after starting the antiepileptic drug perampanel, which had not been previously reported as a side effect.

This review discusses the dual role of apoptotic vesicles in disease and therapy, emphasizing their potential in cancer treatment and tissue regeneration, but reports no new results.

This study suggests that compounds from turmeric and bitter have potential antiviral activity against the influenza A virus by inhibiting the polymerase PA-PB1, warranting further experimental verification.

This study found that finasteride reduced impulsivity in a rat model of pramipexole-induced probability discounting, possibly by normalizing D3 receptor expression in the nucleus accumbens.

This study evaluates the effectiveness and safety of 2-mg and 4-mg doses of baricitinib in patients with alopecia areata who have lost at least 50% of their scalp hair, comparing outcomes between those with early and late onset of the disease.

This study suggests that apremilast shows prolonged efficacy for up to 2 years in hidradenitis suppurativa patients who initially responded to the treatment, although further verification in a larger cohort is needed.

This study found that 4-aminopyridine significantly enhanced skin wound healing by accelerating wound closure, improving skin architecture, and promoting hair follicle neogenesis and tissue regeneration.

This study found that treatment with ritlecitinib or brepocitinib was effective in improving scalp hair loss for patients with alopecia areata over 24 weeks compared to placebo.

This observational study found that while 96.6% of patients using valproic acid showed the expected clinical response, over half experienced adverse reactions like weight gain, hair loss, and hepatotoxicity, highlighting the need for personalized treatment approaches to minimize these side effects.

In this study on mice, a baricitinib-loaded microneedle patch enhanced hair growth in alopecia areata lesions (68% vs control: 33%, p < 0.05), suggesting it may deliver treatment effectively and pain-free, with fewer systemic side effects.

This study found that overexpression of the enzyme SSAT in a mouse model significantly reduced prostate tumor size and progression, suggesting it could be a promising strategy against prostate cancer.

In this study, UPA at doses of 15 mg and 30 mg showed higher efficacy than placebo for treating severe alopecia areata in adults and adolescents over 24 weeks, with a safety profile similar to approved uses.

This study found that CPA-loaded nanoparticles, particularly SLN formulations, increased CPA epidermal penetration compared to a conventional cream and may reduce side effects in treating androgen-dependent conditions.

This phase I study reported that ETC-159, targeting Wnt signalling, showed tolerable safety profiles at doses that inhibit its pathway, though bone turnover markers increased, warranting early and regular monitoring. No tumor responses were observed, but two patients achieved stable disease for several cycles.

This review discusses the potential use of Adiantum capillus-veneris extract for COVID-19 symptom management and reports no clinical findings, highlighting a need for trials to evaluate its efficacy.

This study describes a new two-step method for effectively removing hair particles from split-thickness skin grafts from the scalp, potentially preventing foreign-body reactions at recipient sites.

Agomelatine might help reduce hair loss caused by valproate.

No results are provided in this article as it lacks an available abstract, making it unclear what effects apremilast and tofacitinib have in a humanized mouse model of alopecia areata.

This study reported that ritlecitinib was generally well tolerated over 72 months in patients aged 12 and older with alopecia areata, with adverse events like headache and nasopharyngitis observed, and safety outcomes consistent with previous studies.

In this study, tebentafusp-tebn improved overall survival in patients with metastatic uveal melanoma compared to standard therapies, despite higher rates of significant adverse events.